TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9015133
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus dose of 10 mg Cr(VI)/L in drinking water (0.5 L swallowed in 2 min)
Study: 9015133
Drug: Repeated exposure
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated exposure to 5 mg Cr(VI)/L in drinking water (1 L/d for 3 days, 3 doses of 0.33 L each day at 6-h intervals)
Study: 9015133
Drug: Repeated exposure
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated exposure to 10 mg Cr(VI)/L in drinking water (1 L/d for 3 days, 3 doses of 0.33 L each day at 6-h intervals)
Study: 9015133
Drug: Overall ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall ingestion of Cr(VI) at 5 and 10 mg Cr(VI)/L
Study: 24069533
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab treatment
Study: 26027814
Drug: Daily conversational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily conversational interactions using remote video telecommunications software
Study: 16740812
Drug: Timely patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely patient feedback in the form of a letter providing recent patient-specific symptoms, medication, and health service use combined with guideline-based recommendations for changes in therapy.
Study: 15494100
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E(2)V + 2.5 mg MPA
Study: 15494100
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E(2)V + 5 mg MPA
Study: 11731187
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E(2) + 1 mg NETA
Study: 11731187
Drug: E(2)V/MPA (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2)V/MPA (increased to 2 mg after 6 months)
Study: 11731187
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose combinations
Study: 8607227
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 mg daily for 3 days, then 2 mg daily for 25 days, titrated to 5 or 10 mg if needed)
Study: 1544220
Drug: Interferon‐alpha 2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐alpha 2b (IFN‐alpha 2b) treatment, 3 x 10(6) U three times weekly for 36 weeks
Study: 1544220
Drug: Interferon‐alpha 2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐alpha 2b (IFN‐alpha 2b) treatment
Study: 3907893
Drug: Third-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-line therapy (general)
Study: 30468238
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (16 g of resistant starch Hi‐Maize® 260)
Study: 24795475
Drug: Single vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccine dose of unadjuvanted split‐virus H1N1 A/California/07/2009 influenza vaccine
Study: 24795475
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of unadjuvanted split‐virus H1N1 A/California/07/2009 influenza vaccine
Study: 22613104
Drug: Compound prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound prescription (radix astragali + codonopsis pilosula + tortoise plastron)
Study: 20830787
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (PEG‐IFN with lamivudine)
Study: 18855259
Drug: Amiloride 2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 2.5-5 mg/day
Study: 18855259
Drug: Enalapril 10-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10-20 mg/day
Study: 15700156
Drug: Medical personnel's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical personnel's evaluation of therapy goals
Study: 10355867
Drug: L-arginine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine intake (3.8 g/d) during diet B
Study: 10355867
Drug: Nitrate/nitrite-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate/nitrite-free diet with no L-arginine intake during diet A
Study: 31094588
Drug: Desogestrel 75
Normalized name: desogestrel 75 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel 75 µg
Study: 29045941
Drug: Other antihypertensives
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensives
Study: 23721750
Drug: 40 g/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g/l carbohydrate, 20 g/l milk protein solution (CP20)
Study: 23721750
Drug: 20 g/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/l carbohydrate, 40 g/l milk protein solution (CP40)
Study: 23721750
Drug: 60 g/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g/l carbohydrate solution (C)
Study: 15569122
Drug: Control (alpha-interferon/ribavirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (alpha-interferon/ribavirin therapy)
Study: 8396086
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg od for 3 days)
Study: 8396086
Drug: Co-amoxiclav (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (625 mg tid for 10 days)
Study: 21852334
Drug: Home monitoring
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home monitoring (HM) with daily spirometry and medical feedback
Study: 9196992
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test (0.1 U/kg of crystalline insulin)
Study: 9196992
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose tolerance test (0.3 g glucose/kg followed by 0.02 U/kg of crystalline insulin)
Study: 1933160
Drug: Bard Biocath
Normalized name: IRRIGATION KIT BARD #750301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bard Biocath catheter (16 F 10‐ml balloon)
Study: 1933160
Drug: Silastic catheter
Normalized name: CATHETER SILASTIC 14FR 5CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silastic catheter (16 F 10‐ml balloon)
Study: 24934738
Drug: Two-session self-hypnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-session self-hypnosis training intervention with recordings and brief weekly reminder telephone calls
Study: 23900128
Drug: 800ml oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800ml oral carbohydrate fluid 8 h before the operation and 400ml oral carbohydrate fluid 2 h before the operation
Study: 23900128
Drug: Stopped oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopped oral implementation 8 h before the operation
Study: 30167644
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 600 mg
Study: 21062637
Drug: Ketamine (0.26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.26 mg/kg bolus followed by 0.25 mg/kg IV infusion)
Study: 17267590
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of Escherichia coli endotoxin (0.3 ng/kg)
Study: 17267590
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of Escherichia coli endotoxin (0.3 ng/kg over 4 hours)
Study: 769550
Drug: Tobramycin at
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin at a daily dose of 1.2 mg/kg body weight, administered by intramuscular injection at 8 or 12 hour intervals
Study: 31493177
Drug: Erlotinib induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib induction at 150 mg/day for 3 months followed by cytotoxic chemotherapy (platinum plus pemetrexed, with or without bevacizumab)
Study: 31493177
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after erlotinib induction
Study: 25946126
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 and PTA 5289 lozenges (108 CFU of each strain/lozenge)
Study: 21240026
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment program of obesity
Study: 21240026
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment program of obesity
Study: 31666688
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 20 ppm
Study: 14530859
Drug: Intravenous sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil (0.35 mg/kg over 20 min)
Study: 10965414
Drug: Digoxin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.5 mg) with DHEC (20 mg)
Study: 10965414
Drug: Digoxin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.5 mg) without DHEC
Study: 8774208
Drug: Isoniazid chemoprophylaxis
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid chemoprophylaxis (10 to 15 mg/kg, twice-weekly)
Study: 29029210
Drug: lesinurad 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: lesinurad 400 mg daily
Study: 11181149
Drug: Interleukin (IL)-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin (IL)-2 immunotherapy (4.5x106 IU twice daily for 5 days every 6 weeks)
Study: 9802132
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg/day)
Study: 27016659
Drug: Active sequential
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active sequential bilateral rTMS
Study: 23613825
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng 1 g day(-1)
Study: 23613825
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng 2 g day(-1)
Study: 23613825
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng 1 g
Study: 15195497
Drug: Subcutaneous tryptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tryptorelin depot (Decapeptyl 3.75)
Study: 15195497
Drug: Subcutaneous tryptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tryptorelin acetate daily (Decapeptyl 0.1 mg)
Study: 15195497
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg tryptorelin acetate daily from day 21 of the cycle
Study: 11468228
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 treatment
Study: 8297196
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment with 1200 mg of norfloxacin
Study: 8297196
Drug: Multiple-day treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-day treatment with 400 mg of norfloxacin twice daily for 7 days
Study: 3177373
Drug: Continuous vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous vancomycin therapy (1-g loading dose followed by 30 mg/L dialysate effluent)
Study: 3177373
Drug: Intermittent vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent vancomycin therapy (2 doses of 30 mg vancomycin/kg body weight, initial dose at diagnosis and second dose 1 week later)
Study: 4392503
Drug: Alpha-receptor blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-receptor blocking drugs (phentolamine and phenoxybenzamine)
Study: 4392503
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride (intravenous infusion)
Study: 22702540
Drug: Erythropoiesis stimulating
Normalized name: Erythropoiesis stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis stimulating agents (ESAs)
Study: 27770799
Drug: Oral bicarbonate
Normalized name: sodium bicarbonate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bicarbonate to achieve serum bicarbonate levels of 24-28 mmol/L
Study: 23020102
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention on caregivers' feeding practices, including enhanced home-prepared recipes and food preparation and hygiene through group training, counselling, and home visits.
Study: 16724579
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of zidovudine (AVIRO-Z 300 mg tablet)
Study: 16724579
Drug: Innovator product
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator product (Retrovir tablet)
Study: 11238508
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol daily
Study: 11238508
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol plus 10 mg dydrogesterone daily
Study: 9542398
Drug: Immunological rehabilitation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunological rehabilitation through various therapeutic methods including drugs, plasmapheresis, hemosorption, electrophoresis, ultrasound.
Study: 8001095
Drug: Nonionic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic low osmolar contrast agent (iomeprol)
Study: 8001095
Drug: Ionic contrast
Normalized name: IONIC CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic contrast agent (meglumine diatrizoate)
Study: 3183633
Drug: Daily acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily acyclovir chemosuppression for 1 year
Study: 3183633
Drug: Intermittent acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent acyclovir therapy (placebo group)
Study: 15840666
Drug: THEO (theophylline)
Normalized name: theophylline Extended Release Oral Capsule [Theo-24]
Approvals — FDA: no, EMA: no, PMDA: no
Description: THEO (theophylline) with loop diuretic (LD)
Study: 15840666
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo (NS) with loop diuretic (LD)
Study: 31163106
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/d and EPA 2 g/d
Study: 31163106
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/d and corn oil placebo
Study: 26220802
Drug: Daily electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily electronic self-monitoring using smartphones for 6 months
Study: 21704290
Drug: Iodine-based skin
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine-based skin preparations followed by a cyanoacrylate-based skin sealant
Study: 21704290
Drug: Skin preparations
Normalized name: human skin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin preparations alone
Study: 19254970
Drug: Volume-targeted ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-targeted ventilation at 4 mL/kg
Study: 19254970
Drug: Volume-targeted ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-targeted ventilation at 5 mL/kg
Study: 19254970
Drug: Volume-targeted ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-targeted ventilation at 6 mL/kg
Study: 11291971
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1,000 mg
Study: 11291971
Drug: 400 gm
Normalized name: vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 gm of fruit daily
Study: 9253564
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled analgesia with morphine
Study: 9253564
Drug: Remifentanil post-operative
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil post-operative infusion
Study: 3755348
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.8 mg
Study: 24214189
Drug: Topiroxostat 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 60 mg
Study: 30218318
Drug: Self-reported monthly
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported monthly non-adherence (ring ever out, out for ≥12 hours)
Study: 30218318
Drug: Composite measure
Normalized name: DRESSING,COMPOSITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite measure of non-adherence (plasma DPV value ≤95 pg/ml and residual ring ≥23.5 mg)
Study: 26908964
Drug: Delamanid, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delamanid, a new drug for the treatment of multidrug-resistant tuberculosis.
Study: 17492425
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol consumption (100 ml whisky, approximately 32 g alcohol daily for 4 weeks)
Study: 15726874
Drug: Talinolol 200
Normalized name: talinolol
DrugBank: Talinolol (DB11770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol 200 mg once daily
Study: 15726874
Drug: Talinolol 300
Normalized name: talinolol
DrugBank: Talinolol (DB11770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol 300 mg once daily
Study: 15726874
Drug: Talinolol 100
Normalized name: talinolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol 100 mg once daily
Study: 2532533
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion during halothane anaesthesia
Study: 2532533
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion during opioid anaesthesia
Study: 2532533
Drug: Recovery index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery index for all patients after discontinuing the infusion
Study: 6405427
Drug: Amylobarbitone sodium
Normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amylobarbitone sodium (200 mg)
Study: 29036257
Drug: Topical DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DNA repair enzyme lotion applied twice daily for 8 weeks
Study: 29036257
Drug: Placebo (Eucerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Eucerin Professional lotion) applied twice daily for 8 weeks
Study: 23333022
Drug: Daily Cone
Normalized name: Pinus strobus cone extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Cone Beam Computed Tomography (CBCT)
Study: 23333022
Drug: Daily Electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Electronic Portal Imaging with Fiducial Markers (EPI-FM)
Study: 23333022
Drug: Weekly controls
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly controls (CBCT and EPI-FM)
Study: 21256073
Drug: Specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific treatment based on the Movement System Impairment (MSI) model
Study: 21256073
Drug: Non-Specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Specific treatment
Study: 18175830
Drug: Local phototherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local phototherapy (one-time treatment)
Study: 15682975
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rifampicin for chemoprophylaxis
Study: 10510918
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine sulfate (MS)
Study: 10510918
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ketorolac tromethamine (KT)
Study: 10510918
Drug: Topical 2.5%
Normalized name: menthol topical 2.5% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2.5% lidocaine/prilocaine gel (Emla)
Study: 1883120
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus conventional antihypertensives
Study: 1883120
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus conventional antihypertensives
Study: 26724841
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of dutasteride
Study: 24630937
Drug: Perceived benefits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived benefits of GM (e.g. reduced threats to crops and a more secure food supply)
Study: 22466467
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine with 75 IU of hyaluronidase as peribulbar injection of 5 mL before surgery
Study: 22466467
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine with 75 IU of hyaluronidase as peribulbar injection of 1 mL or 3 mL before surgery
Study: 22466467
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30 patients without any additional analgesic treatment)
Study: 22466467
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine with 75 IU of hyaluronidase as peribulbar injection of 5 mL after surgery
Study: 18039077
Drug: High-loading dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-loading dose regimen of liposomal amphotericin B (L‐AMB)
Study: 18039077
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing regimen of liposomal amphotericin B (L‐AMB)
Study: 12124952
Drug: Intra-atrial infusion
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-atrial infusion of heparin and tissue plasminogen activator (t-PA)
Study: 12124952
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and streptokinase